Home THIS WEBSITE IS INTENDED FOR HEALTHCARE PROFESSIONALS (HCPs) ONLY

Watch how SYLVANT® gets to work

03:37

Play the video to learn how SYLVANT® works to achieve a durable tumor and symptomatic response.

MODE OF ACTION

Interleukin-6 (IL-6) plays a central role in idiopathic Multicentric Castleman Disease (iMCD) pathology, biochemical alteration and symptomatology. It is hypothesised that IL-6 drives plasma cell proliferation and systemic manifestations.1,2

SYLVANT® is a monoclonal antibody that binds to soluble human IL-6 with high affinity, preventing it from binding IL-6 receptors (both soluble and membrane bound).2 Consequently the IL-6 signaling pathway is disrupted, inhibiting the cytokine’s pleiotropic pro-inflammatory effects.

Mode of action

IL-6 signalling in a patient with iMCD. An uninhibited overproduction of IL-6 is the most common pathological driver of iMCD and its symptoms.1,2 IL-6 signalling occurs when the protein interacts with soluble IL-6R. In association with the signal transducer gp130, this complex results in dimerisation and activation of the JAK/STAT signalling cascade.1

Mode of action

Mechanism of action in an iMCD patient treated with SYLVANT®. SYLVANT® prevents the binding of the protein IL-6 to both soluble and membrane-bound IL-6R, thus inhibiting the formation of the hexameric signaling complex with gp130 on the cell surface.1 This binding of SYLVANT® to IL-6 therefore blocks the downstream signaling cascade.3 It’s hypothesised that this prevents the proliferation of plasma cells.1

 

References

  1. SYLVANT® EU Summary of Product Characteristics (Sept 2019)
  2. Sarosiek S, Shah R, Munshi NC. Review of siltuximab in the treatment of multicentric Castleman’s disease. Ther Adv Hematol. 2016;7(6):360-6.
  3. Van Rhee F, vooRhees P, Dispenzieri A, et al. Blood. 2018; 132 (20): 2115-2125.
  4. Van Rhee F, et al. Hematol Oncol Clin N Am. 2018; 32: 89–106.

Abbreviations:
gp130, glycoprotein 130; HHV-8, human herpesvirus-8; HIV, human immunodeficiency virus; IL-6, interleukin-6; IL-6R, IL-6 receptor; iMCD, idiopathic Multicentric Castleman Disease; mAb, monoclonal antibody.

EUSA Sylvant © 2021 EUSA Pharma      Date of prep: November 2021    GL-SIL-2100104

This medicinal product is subject to additional monitoring.
Adverse events to medicinal products should be reported.
Reporting forms and information can be found at your local health authority website.
To report a potential adverse event with an EUSA product please send an email to safety@eusapharma.com.
This website is developed and funded by EUSA for healthcare professionals only.
This website will not collect any personal or private information.

© 2021 EUSA Pharma - Registered in England No. 9329429
Registered office: Breakspear Park, Breakspear Way, Hemel Hempstead, Hertfordshire, HP2 4TZ